Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME)

Launched by INSTITUT CURIE · Jun 5, 2020

Keywords

ClinConnect Summary

The SALOME trial is studying how to better follow up with patients who have uveal melanoma, a type of eye cancer, by looking for specific markers in their blood. These markers can help doctors identify early signs of liver metastases, which is when the cancer spreads to the liver. The goal is to provide a more personalized follow-up plan based on each patient's risk of relapse after their initial treatment.

To be eligible for this study, participants must be at least 18 years old and have a high risk of their cancer coming back, as determined by certain factors related to their tumor and chromosomes. They should also have completed treatment for their primary tumor within the last two months and be able to attend scheduled visits for blood tests. Participants will need to sign a consent form to join the trial. This study is currently recruiting participants of all genders, and it offers a chance to contribute to important research that could improve outcomes for people with uveal melanoma.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patient aged of 18 years or more.
• 2. Patient with uveal melanoma with high metastatic relapse risk defined as :
• • T2b/c/d ou ≥ T3,
• • or chromosom 3 or chromosom 8 abnormality by CGH array.
• • 3. Completion of treatment of the primary tumor ≤ 2 months.
• • 4. Patient able to comply with the schedule of visits and blood samples of the study.
• • 5. Signed informed consent form or legal representative.
• Exclusion Criteria:
• • 1. Patient without french social insurance.
• • 2. Any social, medical or psychological condition making the research process impossible.